{'fraction_non_alphanumeric': 0.023868312757201648, 'fraction_numerical': 0.01728395061728395, 'mean_word_length': 5.235897435897436, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Initial clinical experience with a new kit formulation of Tc‐99m-β galactosylated albumin for functional hepatic imaging

We studied the biodistribution, imaging characteristics and pharmacokinetics of a new kit formulation of Tc-99m-β galactosylated albumin (NGA). In all subjects, even in those patients with severe hepatocellular dysfunction, Tc99m-NGA provided excellent hepatic images and the liver was the only site of uptake of the tracer. Between 2 and 15 min post injection, the blood disappearance curve was found to be adequately described by a mono-exponential function. The fractional desappearance rate (ki) ranged from 0.089 min-1 in normals to 0.039 in cirrhotic patients. The initial volume of distribution (VDi) of the tracer was always higher than the expected blood volume, the difference ranging from 5% in patients with the most impaired liver function to 54% in those with normal liver function. Both parameters discriminated completely the cirrhotic patients from the normal control group. A significant dose dependency of VDi was observed indicating that at least during the minutes after injection liver uptake is determined by both available receptor concentration and hepatic blood flow.